Lead Product(s): Telazorlimab
Therapeutic Area: Dermatology Product Name: ISB 830
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.